

MVP Health Care Medical Policy

Medicare Part B: Syfovre

Type of Policy: Medical Therapy

Prior Approval Date: 01/01/2024
Approval Date: 02/01/2024
Effective Date: 02/01/2024

Related Policies: Orphan Drug(s) and Biologicals

Refer to the MVP Medicare website for the Medicare Part D formulary and Part D policies.

Drugs Requiring Prior Authorization under the medical benefit

J2781 Syfovre (pegcetacoplan) solution for injection

Overview

Syfovre (pegcetacoplan) solution for intravitreal injection is a parenteral complement (C3) inhibitor. It is FDA approved for the treatment of geographic atrophy (GA) secondary to the dry advanced form of age-related macular degeneration (AMD). GA is an irreversible eye disease.

Indications/Criteria

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Syfovre may be considered for coverage when:

- Prescribed and administered by an ophthalmologist
- Chart notes confirming the diagnosis of GA secondary to AMD
- Best-corrected visual acuity (BCVA) ≥24 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) charts or approximate Snellen equivalent of 20/300

Initial approval will be for 6 months.

Subsequent approvals will be for up to 1 year duration and require documentation of clinical benefit.

Exclusions

The use of Syfovre will not be covered for the following situations:

- Members with ocular or periocular infections
- Members with active intraocular inflammation
- Age, dosage, and/or frequency outside of the FDA approved package labeling
- GA secondary to a condition other than AMD such as Stargardt disease in either eye

References

- 1. Syfovre (pegcetacoplan). Clinical Pharmacology. Revised February 24, 2023. Accessed June 5, 2023.
- 2. Syfovre (pegcetacoplan). Prescribing Information. Apellis Pharmaceuticals, Inc. Waltham, MA. Revised February 2023. <u>PI_SYFOVRE.pdf (apellis.com)</u>.
- 3. Apellis. (2023, April). *SyfovreTM (Pegcetacoplan Injection)*. Syfovre. https://syfovreecp.com/
- 4. Prevent Blindness (n.d.). *Eye Diseases & Conditions*. Retrieved June 5, 2023, from https://preventblindness.org/geographic-atrophy/